Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Am J Hematol. 2013 Jan 22;88(3):172–178. doi: 10.1002/ajh.23383

Figure 1.

Figure 1

Change in hematological parameters, organ volume, and biomarkers relative to baseline during 12 months’ treatment with velaglucerase alfa. Mean change from baseline (90% CI) through 12 months’ treatment with velaglucerase alfa for hemoglobin concentrations (indicated as absolute change; A) and platelet counts (indicated as percentage change; B). Mean percentage change from baseline (90% CI) through 12 months’ treatment with velaglucerase alfa for spleen volume (C) and liver volume (D). Mean percentage change from baseline (90% CI) through 12 months’ treatment with velaglucerase alfa for chitotriosidase activity (E) and CCL18 levels (F). One patient deficient in chitotriosidase was excluded from the analysis of chitotriosidase activity.